SAN DIEGO, Feb. 23, 2017 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will be presenting at the Cowen & Company 37th Annual Healthcare Conference in Boston on Tuesday, March 7 at 11:20 a.m. ET/8:20 a.m. PT. Dr. Helen Torley, president and chief executive officer will provide a corporate overview. On Wednesday, March 15, Halozyme will also present at the Barclays Capital Global Healthcare Conference in Miami at 4:50 p.m. ET/1:50 p.m. PT. Laurie Stelzer, senior vice president and chief financial officer, will provide a corporate overview.
The presentations will be webcast through the "Investors" section of www.halozyme.com, and a recording will be made available for 90 days following each event. To access the live webcast, please visit Halozyme's website approximately 15 minutes prior to the presentation to register and download any necessary audio software.
Halozyme Therapeutics is a biotechnology company focused on developing and commercializing novel oncology therapies that target the tumor microenvironment. Halozyme's lead proprietary program, investigational drug PEGPH20, applies a unique approach to targeting solid tumors, allowing increased access of co-administered cancer drug therapies to the tumor in animal models. PEGPH20 is currently in development for metastatic pancreatic cancer, non-small cell lung cancer, gastric cancer, metastatic breast cancer and has potential across additional cancers in combination with different types of cancer therapies. In addition to its proprietary product portfolio, Halozyme has established value-driving partnerships with leading pharmaceutical companies including Roche, Baxalta, Pfizer, Janssen, AbbVie and Lilly for its ENHANZE™ drug delivery platform. Halozyme is headquartered in San Diego. For more information visit www.halozyme.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/halozyme-therapeutics-to-present-at-upcoming-healthcare-conferences-300412824.html
SOURCE Halozyme Therapeutics, Inc.